GLP-1 receptor agonists × pharmacokinetics & dosing

TrialDiabetes, obesity & metabolism2016

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

Mark M Smits et al.PubMed ↗Full text ↗Publisher ↗

  • Liraglutideno clear effectHigher serum levels of deoxycholic acid in the fasting state.Nothing cleared the noise.

What the trial testedas reported · 2016

Not counted

Probably raised serum levels of deoxycholic acid in the fasting state

+0.20µmol/L+0.03 to +0.38

liraglutide vs placebo

As reported

difference 0.20 µmol/L, 95% CI 0.03–0.38

Who was studied, and how

people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

liraglutide
placebo

Probably raised serum levels of deoxycholic acid in the fasting state+0.20

randomised

the abstract, start to end

deoxycholic acid in the fasting state [0.20 µmol/L (95% CI 0.027-0.376),

← favours treatmentfavours comparator →
could be chance
Serum levels of deoxycholic acid in the fasting stateliraglutide vs placebo
0.200.03–0.38
GLP-1 receptor agonistsPharmacokinetics & dosing
1 / 4

31 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27451030